A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Corporate Overview Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In 2000, Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In 2001, Cytomedix, filed for bankruptcy, from which it emerged in 2002 under a Plan of Reorganization. In September 2007, Cytomedix received Section 510(k) clearance from the U. S. Food and Drug Administration (“FDA”) for the AutoloGel™ System, now known as the Aurix System (“Aurix”), for processing peripheral blood into an autologous platelet rich plasma ("PRP") for wound management . In 2010, Cytomedix acquired the Angel Whole Blood Separation System from Sorin Group USA, Inc. In 2012, Cytomedix, acquired Aldagen, Inc.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 2.6M | 1.4M | - | - | 0 | 0 |
| Net Income | -2.4M | -2.3M | -3.2M | -3.2M | -886K | - |
| EPS | $-0.05 | $-0.05 | $-0.08 | $-0.08 | $-0.03 | $0.30 |
| Free Cash Flow | -1.2M | -2.4M | -3.2M | -3.8M | -120K | -54K |
| ROIC | -105.2% | -1757.3% | -133.3% | -86.1% | -4.9% | - |
| Gross Margin | 70.4% | 77.8% | - | - | - | - |
| Debt/Equity | 0.00 | 0.32 | 0.25 | 0.15 | 0.00 | -0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.6M | -2.5M | -3.2M | -3.3M | -91K | -378K |
| Operating Margin | -98.3% | -180.0% | - | - | - | - |
| ROE | 0.0% | -299.3% | -305.2% | -144.7% | -111.8% | - |
| Shares Outstanding | 48M | 46M | 40M | 40M | 30M | 37M |
Nuo Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 77.8%.
Nuo Therapeutics, Inc. (AURX) has a 5-year average return on invested capital (ROIC) of -74.8%. This is below average and may indicate limited pricing power.
Nuo Therapeutics, Inc. (AURX) has a market capitalization of $69M. It is classified as a small-cap stock.
Nuo Therapeutics, Inc. (AURX) does not currently pay a regular dividend.
Nuo Therapeutics, Inc. (AURX) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Nuo Therapeutics, Inc. (AURX) reported annual revenue of $1 million in its most recent fiscal year, based on SEC EDGAR filings.
Nuo Therapeutics, Inc. (AURX) has a net profit margin of -170.2%. The company is currently unprofitable.
Nuo Therapeutics, Inc. (AURX) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Nuo Therapeutics, Inc. (AURX) has a debt-to-equity ratio of 0.32. This indicates a conservatively financed balance sheet.
Nuo Therapeutics, Inc. (AURX) reported earnings per share (EPS) of $-0.05 in its most recent fiscal year.
Nuo Therapeutics, Inc. (AURX) has a return on equity (ROE) of -299.3%. A negative ROE may indicate losses or negative equity.
Nuo Therapeutics, Inc. (AURX) has a 5-year average gross margin of 77.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for Nuo Therapeutics, Inc. (AURX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Nuo Therapeutics, Inc. (AURX) has a book value per share of $0.01, based on its most recent annual SEC filing.